I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Italy

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology ARVO 2024
Roche and Genentech at

ARVO 2024

May 05 - May 09
Seattle, Washington
arvo.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
04:30 PM
Duration 30mins Seattle, Washington
Automated Segmentation of Hard Exudates Using SD-OCT in Patients with Diabetic Macular Edema from the Phase 2b ALTIMETER Study
Maunz A, Parian-Scherb M, Cohen Y, Bachmeier I, Yu S, Gibson K, Mar F, Xue Z, Glittenberg C
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:00 PM
Duration 105mins Seattle, Washington
Defining the Role of Angiopoietin-2 in Vascular Destabilization Using Primary Human Vasculature Models
Westenskow P, Stoll, R, Spielmann A, Kim B, Ragelle H
Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Extended treatment outcomes and the potential for Q20W dosing with faricimab▼ in nAMD: a post hoc analysis of the pivotal TENAYA/LUCERNE trials
Storey P, Koh A, Singer M, Hill L, Kotecha A, Margaron P
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:30 PM
Duration 105mins Seattle, Washington
Faricimab▼ treatment outcomes with extended dosing and potential for Q20W intervals in DME: post hoc analysis of the 96-week phase 3 YOSEMITE/RHINE trials
Adam M, Gibson K, Sim D, Amador M, Hill L, Singer M
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Deep learning to identify diffuse retinal thickening (DRT) on optical coherence tomography (OCT)
Dimitrios Damopoulos, Tom Albrecht, Ali Valcarcel, Derrek Hibar, Mike Chen, Dinah Chen, Vivian Look, Vivide Chang, Daniela Ferrara, Huanxiang Lu
Ophthalmology | Diabetic Macular Edema - Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:00 PM
Duration 105mins Seattle, Washington
Longitudinal Quantitative Ultra-Widefield Fluorescein Angiography Leakage Dynamics in Patients With Uveitic Macular Edema Following Intravitreal Anti–IL-6 Therapy With Vamikibart
Cakir Y, Matar K, Cetin H, Amine R, Bonnay M, McConville C, Srivastava S, Pauly-Evers M, Holmes W, Barekati Z, Storti F, Fauser S, Mesquida M, Sharma S, Ehlers J
Ophthalmology | Uveitis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Intravitreal Interleukin-6 Inhibition With Vamikibart in Sarcoidosis-Associated Uveitis
Pauly-Evers M, Barekati Z, Storti F, Holmes W, Steeples L, Haskova Z, Lin P, Sharma S, Fauser S, Mesquida M
Ophthalmology | Uveitis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Deep Learning-Based Optical Coherence Tomography Segmentation of Retinal Fluids and Layers Using Multi-Grader Annotations
Pla Alemany S, Albrecht T, Valcarcel A, Hibar D, Chen M, Chen D, Look V, Chang V, Ferrara D, Lu H
Ophthalmology | Age Related Macular Degeneration - Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Predicting Geographic Atrophy Growth Rate With Clinical and Derived Imaging Features
Julia Cluceru, Ondrej Slama, Neha Anegondi, Simon S Gao, Daniela Ferrara, Michel Friesenhahn, Christina Rabe
Ophthalmology | Geographic Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials
Suhler E, Steeples L, Elze M, Macgregor L, Silverman D, Haskova Z
Ophthalmology | Uveitis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Generalizability of foundation models for geographic atrophy (GA) lesion segmentation in fundus autofluorescence (FAF)
Gros E, McLeod M, Kikuchi Y, Cluceru J, Anegondi N, Gao S, Rabe C, Ferrara D, Yang Q
Ophthalmology | Geographic Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 15mins Room 6E (Seattle Convention Center - Arch Building)
Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab▼: The FARETINA-AMD Study
Tabano D, Ko S, Borkar D, Leng T, Ali F, Shaia J, Myers R, LaPrise A, Singh R
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:30 PM
Duration 105mins Seattle, Washington
Volumetric Fluid Dynamics Using Machine-Learning Augmented Analysis in Patients With Uveitic Macular Edema Receiving Vamikibart in the DOVETAIL Study
Matar K, Cakir Y, Cetin H, Amine R, Bonnay M, McConville C, Srivastava S, Pauly-Evers M, Holmes W, Barekati Z, Storti F, Fauser S, Mesquida M, Sharma S, Ehlers J
Ophthalmology | Uveitis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Longitudinal Quantitative Anterior Chamber Cell Analysis Following Vamikibart Intravitreal Therapy in Patients With Uveitic Macular Edema From the DOVETAIL Clinical Trial
Sharma S, Hamdan A, Chen C, Le P, Baynes K, Pauly-Evers M, Holmes W, Barekati Z, Storti F, Fauser S, Mesquida M, Srivastava S, Singh S
Ophthalmology | Uveitis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Efficacy, safety, and durability of faricimab▼ in macular edema due to retinal vein occlusion: 72-week results from the BALATON and COMINO trials
Ghanchi F, Abreu F, Arrisi P, Kotecha A, Liu Y, Paris L, Retiere A, Willis J
Ophthalmology | Retinal Vein Occlusion

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Aqueous Humor Interleukin-6 Levels in Uveitic Macular Edema: Baseline Characteristics From the Phase 1 DOVETAIL Study
Barekati Z, Holmes W, van Donge T, Pauly-Evers M, Jordan G, Sickert D, Peck R, Willen D, Passemard B, Fauser S, Mesquida M, Storti F
Ophthalmology | Uveitis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:15 PM
Duration 105mins Seattle, Washington
Predicting functional outcomes for different treatment durations of faricimab in diabetic macular edema (DME)
Kikuchi Y, Abderezaei J, McLeod M, Chen C, Benech AC, Ferrara D, Anegondi N, Yang Q
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:00 PM
Duration 15mins Room 6E (Seattle Convention Center - Arch Building)
Port Delivery System with ranibizumab (PDS) met primary endpoint and key secondary outcomes with >75% of patients preferring PDS treatment in phase 3 Pavilion trial for diabetic retinopathy (DR)
Latkany P, Regillo C, Wykoff C, Chang M, Emanuelli A, Holekamp N, Malhotra V, Howard D, Santhanakrishnan A, Wetzel-Smith M, Quezada-Ruiz C, Pieramici D
Ophthalmology | Diabetic Retinopathy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 15mins Room 6E (Seattle Convention Center - Arch Building)
Real-world treatment patterns and outcomes in the first 6 and 12 months of faricimab▼ use among eyes with neovascular age-related macular degeneration (nAMD) in the UK: FARWIDE-nAMD
Varma D, Talks J, DeSalvo G, Patel P, DeSilva S, Gale R, McKibbin M, Chi G, James N, Rothwell A, Shah N, Downey A, Dodds M, Dayal P
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:30 PM
Duration 15mins Room 6E (Seattle Convention Center - Arch Building)
Impact of Early Intraretinal Fluid Reduction on One-Year Outcomes in Diabetic Macular Edema
Wang Y, Hibar D, Maunz A, Lu H, Albrecht T, Gibson K, Willis J, Chang D, Litts K
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:00 PM
Duration 105mins Seattle, Washington
Retinal vasculitis with or without retinal vascular occlusion among eyes with nAMD or DME treated with IVT agents as recorded in the Vestrum database
Patel S, Chi G, Aggarwal N, Amador M, Boucher N, Chang SC, Patel V, Sharma S, Zarbin M
Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Clinical pearls from the TENAYA/LUCERNE trials of faricimab▼ in patients with nAMD
Haug S, Amador M, Kotecha A, Margaron P, Stoilov I, Tang Y
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Greater reduction in pigment epithelial detachment size in TENAYA/LUCERNE with faricimab▼ 6.0 mg vs aflibercept 2.0 mg during head-to-head dosing in patients with nAMD
London N, Khanani A, Lai T, Lim J, Kotecha A, Margaron P, Patel S, Souverain A, Willis J, Yang M
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Towards automated optical coherence tomography (OCT) data analysis for a real-world diabetic macular edema (DME) treatment cohort
Talks J, Peto T, Wang X, Gershon A, Menon G, Ghanchi F, Chen X, Look V, Lu H, Chen M, Ferrara D, Chi G, Yang Q
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Faricimab treatment response prediction in diabetic macular edema (DME) using deep learning on optical coherence tomography (OCT) and clinical data
McLeod M, Abderezaei J, Kikuchi Y, Chen C, Benech AC, Ferrara D, Anegondi N, Yang Q
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:45 PM
Duration 105mins Seattle, Washington
Greater reduction in hard exudates with faricimab▼ vs aflibercept in patients with DME: biomarker results from the phase 3 YOSEMITE/RHINE trials
Goldberg R, Amador M, Dinah C, Gibson K, Glittenberg C, Maunz A, O'Leary O, Rahimy E, Uschner D
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Key clinical and anatomic outcomes from the YOSEMITE/RHINE trials of faricimab▼ in patients with DME
Manoharan N, Amador M, Willis J,Stoilov I, Mar F, Gibson K, Abreu F
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Real-World Treatment Patterns and Outcomes in the First 6 and 12 Months of Faricimab▼ Use Among Eyes With Diabetic Macular Edema (DME) in the UK: FARWIDE-DME
Reynolds R, Peto T, Bailey C, Downey L, Kiire C, Pearce I, Sivaprasad S, Chi G, James N, Rothwell A, Shah N, Downey A, Dodds M, Dayal P
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Treatment outcomes with anti-VEGF therapy for retinal vein occlusion: an analysis of real-world data from 16 UK sites
Dinah C, Dodds M, Arrisi P, Pereira L, Lake A, Nielsen P, Holdsworth J, Saffar I, Chi G
Ophthalmology | Retinal Vein Occlusion

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Efficacy and Safety of Faricimab▼ in ALTIMETER: A Trial Exploring Biomarkers of Ang-2 Inhibition in Patients With DME
Gibson K, Dang S, Amador M, Dieckmann A, Glittenberg C, Kotak A, Mar F, Souverain A, Titz B, Vujosevic S, Fawzi A
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Real-world clinical and anatomical outcomes in patients with diabetic macular edema treated with faricimab▼: The FARETINA-DME study
Borkar D, Tabano D, Ko S, Leng T, Shaia J, Myers R, LaPrise A, Ali F, Singh R
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Elevatum study design and rationale: a phase 4 trial of faricimab▼ (VABYSMO) in underrepresented patients with DME
Brown J, Cunningham M, Coney J, Scott A, Amador M, Chang J, Yang M, Stoilov I, Gonzalez L
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Port Delivery System with ranibizumab (PDS) stabilizes retinal nonperfusion and macular leakage: results from Pagoda and Pavilion phase 3 trials in diabetic macular edema (DME) and diabetic retinopathy (DR)
Wirthlin R, Gill M, Howard D, Menezes A, Rahman S, Latkany P
Ophthalmology | Diabetic Retinopathy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Port Delivery System With Ranibizumab (PDS) in diabetic macular edema (DME): additional primary analysis results of the phase 3 Pagoda trial
Malhotra V, Klufas M, Marcus D, Graff J, Campochiaro P, Rahman S, Latkany P, Gune S, Lin S, DeGraaf S, Bobbala A, Rabena M, Quezada-Ruiz C, Khanani A
Ophthalmology | Diabetic Retinopathy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 105mins Seattle, Washington
Pharmacokinetic (PK) profile of the Port Delivery System with ranibizumab (PDS) in the phase 3 Pagoda and Pavilion trials
Heinrich D, Wolfe J, Dhoot D, Ding HT, Hyung S, Latkany P, Maass K, Rahman S, Hsu J
Ophthalmology | Diabetic Retinopathy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.